SLC家族在三阴性乳腺癌代谢中的研究进展  

Research progress of SLC family in triple-negative breast cancer metabolism

作　　者：李雪 孙立[1] LI Xue;SUN Li(New Drug Screening and Pharmacodynamics Evaluation Center,State Key Laboratory of Natural Medicines,China Pharmaceutical University,Jiangsu,Nanjing 210000,China)

机构地区：[1]中国药科大学多靶标天然药物全国重点实验室新药筛选与药效评价中心,江苏南京210000

出　　处：《中国医药科学》2024年第22期13-16,共4页China Medicine And Pharmacy

基　　金：国家自然科学基金(82272668)。

摘　　要：近年来,靶向溶质载体(SLC)家族已成为癌症药理学和药物发现领域的研究热点。SLC家族转运蛋白参与多种溶质(无机离子、氨基酸、神经递质和药物等)的跨膜运输及维持细胞的代谢。自20世纪20年代Warburg效应被发现以来,癌细胞内的代谢重编程现象已被普遍接受。作为癌症进展的标志,代谢重编程为癌症的诊断、预后以及治疗提供了研究的方向。有关SLC家族的研究涉及多种肿瘤的代谢进程。然而,SLC家族在三阴性乳腺癌(TNBC)代谢中的相关报道较少。因此,本文回顾SLC家族在TNBC代谢中的功能及与癌症进展的关系,并对近期报道的SLC靶点进行总结。In recent years,the targeted solute carriers(SLC)family has become a research hotspot in the field of cancer pharmacology and drug discovery.SLC family transporters participate in the transmembrane transport of various solutes(inorganic ions,amino acids,neurotransmitters and drugs)and maintain cell metabolism.Since the Warburg effect was discovered in the 1920s,metabolic reprogramming in cancer cells has been widely accepted.As a sign of cancer progress,metabolic reprogramming provides a research direction for the diagnosis,prognosis and treatment of cancer.The research on SLC family involves the metabolic process of many tumors.However,there are relatively few reports about SLC family in the metabolism of triple-negative breast cancer(TNBC).Therefore,the correlation between the function of SLC family in TNBC metabolism and cancer progression is reviewed,and the SLC targets reported recently are summarized in this paper.

关 键 词：三阴性乳腺癌 溶质载体家族 代谢 肿瘤 

分 类 号：R737.9[医药卫生—肿瘤]